Literature DB >> 9356790

Practice guidelines for community-based parenteral anti-infective therapy. ISDA Practice Guidelines Committee.

D N Williams1, S J Rehm, A D Tice, J S Bradley, A C Kind, W A Craig.   

Abstract

This is the fourth in a series of practice guidelines commissioned by the Infectious Diseases Society of America through its Practice Guidelines Committee. The purpose of this guideline is to provide assistance to clinicians when making decisions on when and how to best administer parenteral antimicrobial therapy. The targeted providers are internists, pediatricians, family practitioners, and other providers of outpatient antiinfective therapy. Criteria for selecting the appropriate patients and settings to deliver therapy in the community are described. Panel members represented experts in adult and pediatric infectious diseases. The guidelines are evidence-based. A standard ranking system is used for the strength of the recommendations and the quality of the evidence cited in the literature reviewed. The document has been subjected to external review by peer reviewers as well as by the Practice Guidelines Committee and was approved by the IDSA Council. An executive summary and tables highlight the major recommendations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356790     DOI: 10.1086/515552

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues.

Authors:  D N Williams; J L Raymond
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

Review 2.  Outpatient therapy for febrile neutropenia: clinical and economic implications.

Authors:  Fausto de Lalla
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 3.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections.

Authors:  Ursula C Patel; Erin L McKissic; Douglas Kasper; Joseph R Lentino; Constance T Pachucki; Todd Lee; Bert K Lopansri
Journal:  Int J Clin Pharm       Date:  2014-09-04

Review 5.  Ambulatory use of parenteral antibacterials: contemporary perspectives.

Authors:  J E Leggett
Journal:  Drugs       Date:  2000       Impact factor: 9.546

6.  The Impact of a Standardized Discharge Process on 30-Day Readmissions for Patients on Outpatient Parenteral Antibiotic Treatment.

Authors:  Charnicia E Huggins; Tae Eun Park; Eric Boateng; Cosmina Zeana
Journal:  Hosp Pharm       Date:  2020-12-29

7.  Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis.

Authors:  J Carratalà; B Rosón; N Fernández-Sabé; E Shaw; O del Rio; A Rivera; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

Review 8.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry.

Authors:  W J Martone; K C Lindfield; D E Katz
Journal:  Int J Clin Pract       Date:  2008-08       Impact factor: 2.503

10.  Bundle in the Bronx: Impact of a Transition-of-Care Outpatient Parenteral Antibiotic Therapy Bundle on All-Cause 30-Day Hospital Readmissions.

Authors:  Theresa Madaline; Priya Nori; Wenzhu Mowrey; Elisabeth Zukowski; Shruti Gohil; Uzma Sarwar; Gregory Weston; Riganni Urrely; Matthew Palombelli; Vinnie Frank Pierino; Vanessa Parsons; Amy Ehrlich; Belinda Ostrowsky; Marilou Corpuz; Liise-Anne Pirofski
Journal:  Open Forum Infect Dis       Date:  2017-06-29       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.